Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 23

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 115,307 Other comprehensive income (loss), net of tax:Unrealized gains on available-for-sale securities653 216 146 2,125 Foreign currency translation adjustments(400)(56)(506)2 Comprehensive income (loss)$368,116 $(126,836)$192,285 $(260,245)

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

2

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity 

(in thousands)

(unaudited)

CommonStockAmount ($)AdditionalPaid-InCapitalAccumulated Other Comprehensive IncomeAccumulatedDeficitNon-controlling InterestTotalBalance at September 30, 2024124,376 $217 $1,806,000 $4,750 $(1,625,523)$5,619 $191,063 Stock-based compensation— — 15,209 — — — 15,209 Exercise of stock options70 — 634 — — — 634 Common stock - restricted stock units vesting209 — — — — — — Issuance of pre-funded warrants— — 25,000 — — — 25,000 Foreign currency translation adjustments— — — (106)— — (106)Unrealized gains on available-for-sale securities— — — (507)— — (507)Net loss— — — — (173,085)(2,133)(175,218)Balance at December 31, 2024124,655 $217 $1,846,843 $4,137 $(1,798,608)$3,486 $56,075 Stock-based compensation— — 16,027 — — — 16,027 Exercise of stock options353 — 2,619 — — — 2,619 Common stock - restricted stock units vesting1,128 1 — — — — 1 Common stock issued11,926 12 241,375 — — — 241,387 Foreign currency translation adjustments— — — (400)— — (400)Unrealized gains on available-for-sale securities— — — 653 — — 653 Net income—